MOTS-c (40 mg Vial) Dosage Protocol

Dosing & Reconstitution Overview

MOTS-c (mitochondrial open reading frame of the twelve S rRNA-c) is a 16-amino-acid mitochondrial-derived peptide studied for its role in metabolic regulation and cellular energy balance. The figures below are compiled strictly for laboratory and educational reference — they describe how the compound has been handled and dosed across published animal and cell studies, not a recommendation for use in humans or animals.

For a 40 mg vial, adding 3.0 mL of bacteriostatic water yields a concentration of roughly 13.33 mg/mL (13,333 mcg/mL). At that concentration, every 0.075 mL drawn on a U-100 insulin syringe equals 7.5 units and delivers about 1000 mcg (1 mg) of material, which keeps the daily microgram-scale arithmetic manageable.

Standard (Gradual) Titration Schedule

The gradual schedule steps the daily amount upward every two weeks, mirroring the slow dose-escalation approach used to model tolerability before reaching the upper end of the studied range.

Reconstitution Steps

1. Let the sealed lyophilized vial and the bacteriostatic water reach room temperature, then wipe both stoppers with an alcohol swab.
2. Draw 3.0 mL of bacteriostatic water and inject it slowly down the inside wall of the vial — never directly onto the powder pellet.
3. Swirl gently until fully dissolved. Do not shake; aggressive agitation can shear the peptide.
4. The solution should be clear and colourless. Label the vial with the concentration (13.33 mg/mL) and the reconstitution date.
5. Store upright under refrigeration between uses and draw each daily volume with a fresh sterile syringe.

Supplies Needed

• MOTS-c vials (40 mg): ~1 vial for an 8-week run; ~2 vials for 12 weeks; ~3 vials for 16 weeks at the upper daily steps.
• Insulin syringes (U-100, 1 mL): ~56 for 8 weeks, ~84 for 12 weeks, ~112 for 16 weeks (one fresh syringe per daily draw).
• Bacteriostatic water (10 mL): a single bottle covers the diluent for these durations.
• Alcohol swabs: roughly two 100-count boxes for 8–12 weeks; three boxes for a 16-week schedule.

Protocol Overview

• Research goal: model metabolic and mitochondrial regulation via AMPK activation.
• Schedule: once-daily subcutaneous administration in the published models.
• Dose band: 200–1000 mcg daily across a gradual 10-week escalation.
• Fill: 40 mg lyophilized, reconstituted to 13.33 mg/mL with 3 mL diluent.
• Storage: −20 °C dry; 2–8 °C once reconstituted.

Dosing Protocol Notes

• Begin at the lowest 200 mcg step and hold each level for about two weeks before escalating.
• Keep administration on a fixed daily cadence and around the same time for steady exposure modelling.
• Escalate only after tolerability is established at the prior step.
• The microgram volumes are small (1.5–7.5 units), so draw carefully and confirm the dose against the syringe markings.

Storage Instructions

Keep sealed lyophilized vials at −20 °C or below, protected from light, where stability extends for many months. Once reconstituted, refrigerate at 2–8 °C and use within about seven days. Allow refrigerated solution to warm slightly before drawing, avoid repeated freeze-thaw cycles, and aliquot if a vial will be sampled many times.

Important Handling Notes

• Use a sterile syringe for every draw and never re-enter the vial with a used needle.
• Rotate sampling/handling technique to keep the stopper intact.
• Confirm small microgram volumes carefully against the syringe scale before each draw.
• Document each draw — date, volume, remaining material — for reproducibility.

How MOTS-c Works

MOTS-c is a peptide encoded within the mitochondrial 12S rRNA region and translated from a short open reading frame. Mechanistically it activates AMP-activated protein kinase (AMPK) — a central energy sensor — in part by interfering with the folate-methionine cycle and driving accumulation of AICAR, which pushes cells toward an energy-conserving state. Through this AMPK axis it is reported to enhance glucose uptake, fatty-acid oxidation and mitochondrial respiration while reducing fat storage. It is notable as one of the mitochondrial-derived peptides that signal between mitochondria and the rest of the cell.

Reported Benefits & Side Effects

Benefits observed in preclinical studies

• Improved insulin sensitivity and glucose metabolism in animal models.
• Prevention of diet-induced insulin resistance and reduced visceral fat.
• Increased energy expenditure and enhanced exercise capacity (aged mice ran roughly twice as long).
• Reduced liver fat, improved cardiac function, promotion of bone formation and modulation of immune aging.

Side effects reported

• No adverse effects were reported across the published preclinical (animal and cell) work.
• Human tolerability and safety remain unknown — no completed human clinical trials exist.
• All efficacy signals to date come strictly from laboratory and animal research.

Supporting Lifestyle Factors (Research Context)

• Exercise is a frequent co-variable in MOTS-c studies, since the peptide is itself exercise-responsive.
• Controlled dietary inputs to model glucose and lipid handling in the published designs.
• Standard trial controls — consistent activity, hydration and rest — to isolate the compound's effect.

Injection Technique (Reference Only)

• Clean the vial stopper and the site with alcohol swabs and let them dry completely.
• Pinch a skinfold and insert subcutaneously at 90° (or 45° for very lean tissue); aspiration is not required for subcutaneous work.
• Inject slowly over several seconds given the small volume.
• Rotate sites systematically — abdomen (at least two inches from the navel), outer thighs, upper arms — and dispose of sharps in an approved container.

References

Related Protocols